News
Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback